Stock CLSD CLEARSIDE BIOMEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Delayed Nasdaq
Other stock markets
 10:50:46 2024-04-29 am EDT 		5-day change 1st Jan Change
1.28 USD -4.48% Intraday chart for Clearside Biomedical, Inc. -9.22% +9.40%
Apr. 16 Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors CI
Mar. 18 Clearside Biomedical Names Victor Chong Chief Medical Officer MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
AQ
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
AQ
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
AQ
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
AQ
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
AQ
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
AQ
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
AQ
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
AQ
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
AQ
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
AQ
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
AQ
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
AQ
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
AQ
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
AQ
Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference
AQ
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLSD Stock
  4. News Clearside Biomedical, Inc.
  5. Press Releases